about
Sex differences in psychiatric comorbidity and plasma biomarkers for cocaine addiction in abstinent cocaine-addicted subjects in outpatient settings.Plasma concentrations of BDNF and IGF-1 in abstinent cocaine users with high prevalence of substance use disorders: relationship to psychiatric comorbidityExpectations among patients and health professionals regarding Web-based interventions for depression in primary care: a qualitative studyEconomic evaluation of a guided and unguided internet-based CBT intervention for major depression: Results from a multi-center, three-armed randomized controlled trial conducted in primary care.An Internet-Based Intervention for Depression in Primary Care in Spain: A Randomized Controlled Trial.Plasma Chemokines in Patients with Alcohol Use Disorders: Association of CCL11 (Eotaxin-1) with Psychiatric Comorbidity.Evaluation of plasma cytokines in patients with cocaine use disorders in abstinence identifies transforming growth factor alpha (TGFα) as a potential biomarker of consumption and dual diagnosis.Decreased plasma concentrations of BDNF and IGF-1 in abstinent patients with alcohol use disorders.Differences in clinical intrusive thoughts between obsessive-compulsive disorder, generalized anxiety disorder, and hypochondria.Differences in the Rates of Drug Polyconsumption and Psychiatric Comorbidity among Patients with Cocaine Use Disorders According to the Mental Health Service.Plasma concentrations of oleoylethanolamide and other acylethanolamides are altered in alcohol-dependent patients: effect of length of abstinence.Psychiatric comorbidity and plasma levels of 2-acyl-glycerols in outpatient treatment alcohol users. Analysis of gender differences.Gender differences in physical activity are partially explained by anxiety sensitivity in post-secondary studentsBupropion, a possible antidepressant without negative effects on alcohol relapsePlasma concentrations of oleoylethanolamide in a primary care sample of depressed patients are increased in those treated with selective serotonin reuptake inhibitor-type antidepressantsCross-cultural selection and validation of instruments to assess patient-reported outcomes in children and adolescents with achondroplasiaVariation in chemokines plasma concentrations in primary care depressed patients associated with Internet-based cognitive-behavioral therapy
P50
Q35087097-75E7320A-39F1-4E35-913D-2BC5534CD767Q35143914-51CEB9A2-1164-467C-A976-EFE2B2724043Q35223243-F624BD5C-66D4-413E-A8C7-7761E4CAA050Q36291479-EBA49C27-2B2B-491E-AC51-06F9CA1F98E6Q37246072-DF54438E-D801-4028-B1CE-B875D1753604Q37592041-8E2D35CB-966F-41F2-A2DA-651EFE70B643Q42377741-5881A9B4-7AF8-47ED-BD9C-31196909ED3FQ43617481-2A4A184D-6E79-4E16-A1BB-CE3F8CE3CA34Q47306619-DAB9D4AA-735F-4124-AF65-25CC0A8E8B9DQ47675654-3B61EFEC-6C25-46D2-98DD-DA1A09156BE3Q48018792-BAC5AEAF-F2CB-437A-9984-CF19BFA610DDQ50227014-995A76B4-17EE-4927-84DE-7C2464E1E8DAQ91053175-3C4F8110-9C04-4FF8-9078-83277D8856B5Q91830668-582E13A0-F3C4-4DF4-8113-E080F20728E0Q92044561-34188F65-B38D-40D6-8809-23FF3ADE9D2AQ92060555-C552F06C-5AD0-401C-80A8-C3F5AB36560DQ92890816-F5BA32F0-5A1F-4380-89F1-C3A97B783370
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Pablo Romero-Sanchiz
@en
Pablo Romero-Sanchiz
@nl
type
label
Pablo Romero-Sanchiz
@en
Pablo Romero-Sanchiz
@nl
prefLabel
Pablo Romero-Sanchiz
@en
Pablo Romero-Sanchiz
@nl
P31
P496
0000-0002-3683-3835